The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked...

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• X-linked adrenoleukodystrophy (X-ALD) is a severe neurometabolic disorder with limited treatment options.
• Current understanding of X-ALD's molecular mechanisms, particularly in cerebral and spinal cord forms, remains incomplete.
• There is a critical need for effective pharmacological interventions to address X-ALD's neuroinflammation and neurodegeneration.

Purpose of the Study:

• To investigate the therapeutic potential of leriglitazone, a PPARγ agonist, for X-linked adrenoleukodystrophy (X-ALD).
• To evaluate leriglitazone's effects on oxidative stress, mitochondrial function, neuroinflammation, and myelin repair in X-ALD models.
• To assess leriglitazone's clinical safety and efficacy, including central nervous system target engagement.

Main Methods:

• Utilized primary rodent neurons and astrocytes exposed to very long chain fatty acid toxicity.
• Employed adrenomyeloneuropathy (AMN) mouse models to assess motor function and spinal cord pathology.
• Tested leriglitazone in an experimental autoimmune encephalomyelitis (EAE) model for neuroinflammation.
• Analyzed X-ALD patient-derived macrophages and monocytes for inflammatory markers and endothelial cell adhesion.
• Investigated leriglitazone's impact on myelination and oligodendrocyte survival in vivo and myelin debris clearance in vitro.
• Conducted a Phase 1 clinical study to evaluate safety, tolerability, and biomarker changes.

Main Results:

• Leriglitazone demonstrated neuroprotective effects by reducing oxidative stress and increasing ATP levels in X-ALD models.
• Improved motor function, restored mitochondrial function, and reduced inflammation in spinal cord tissues of AMN mice.
• Decreased neurological disability in the EAE model and reduced inflammatory skewing in X-ALD patient macrophages.
• Showed potential to prevent blood-brain barrier disruption and enhanced myelin debris clearance.
• Promoted remyelination, increased oligodendrocyte survival, and demonstrated CNS target engagement in a Phase 1 study.

Conclusions:

• Leriglitazone exhibits significant therapeutic potential for X-linked adrenoleukodystrophy (X-ALD) by targeting key pathological pathways.
• The drug's multifaceted effects on neuroprotection, inflammation, and remyelination support its advancement for X-ALD treatment.
• Leriglitazone may also hold promise for broader applications in other neuroinflammatory and neurodegenerative diseases.